Your Go-To Tools and Resources

For Healthcare Professionals

Access these tools to help optimize the Rasuvo experience

Copay card image

Help your patients save

The Co-pay Assistance Program can provide financial support of up to $125 per month for 14 months.*

  • 85% of patients who used the co-pay card had a $0 co-pay1,
  • Preferred on many formularies
    • 84% of commercial lives covered, 46% preferred brand2
  • Available on insurance plans serving over 156 million patients2

Rasuvo has the most comprehensive coverage of any scMTX Auto-Injector2,

  • CVS Caremark®
  • Express Scripts®
  • Humana®
  • Cigna®
  • UnitedHealth Group®
  • Highmark Health®
  • HCSC®
  • Anthem®
  • OptumRx®
  • Preferred
  • Covered

*For eligible patients.

Data from April 2016 to April 2017.

Average nationwide coverage of methotrexate auto-injectors. Individual coverage may vary.

All brand or product names are registered trademarks of their respective owners.

*For eligible patients.

Core Connections logo

Practice Resources

Utilize CORE Connections—a program that supports Rasuvo® (methotrexate) injection patients with educational materials, financial assistance, insurance forms, and more.

Dollar sign

For reimbursement services and patient eligibility determinations, call the Rasuvo Benefits Support Line at 1-855-336-3322, from 8:00 am to 8:00 pm EST Monday-Friday (excluding holidays).

Video practice resources

Show your patients a video demonstration.

See Auto-Injector: 3 Easy Steps Video

Auto-injector ease of use

Compared to the syringe and vial method of MTX administration, Rasuvo makes it easier to deliver MTX subcutaneously. The prefilled auto-injector eliminates the need for preparing doses by hand.3-5

3-Step Delivery of Rasuvo
Remove the yellow cap
Prepare the injection
Inject Rasuvo

Download the patient injection instruction sheet for complete instructions.

Photo of person using phone

Patient Resources

Give your patients the support they need to help optimize MTX starting today.

References: 1. Data on file. Medexus Pharma, Inc. 2. Rheumatoid arthritis database. Yardley, PA: Managed Markets Insight & Technology, LLC (MMIT): August 2019. 3. Demary W, Schwenke H, Rockwitz K, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061-1071. 4. Pachon JA, Kivitz AJ, Heuer KU, Pichlmeier U. Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis. SAGE Open Med. 2014;2:1-12. 5. Rasuvo [prescribing information]. Chicago, IL: Medac Pharma, Inc.; 2018.


Rasuvo is indicated for the:

Limitations of Use

Rasuvo is not indicated for treatment of neoplastic diseases.

This product includes the following Boxed Warning:


Rasuvo should be used only by physicians whose knowledge and experience include the use of antimetabolite therapy. Because of the possibility of serious toxic reactions (which can be fatal), Rasuvo should be used only in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician's care throughout therapy.

  1. Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, Rasuvo is not recommended for females of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Rasuvo is contraindicated in pregnant women.
  2. Methotrexate elimination is reduced in patients with impaired renal functions, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of Rasuvo administration.
  3. Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs).
  4. Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population.
  5. Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation.
  6. Diarrhea and ulcerative stomatitis require interruption of therapy: otherwise, hemorrhagic enteritis and death from intestinal perforation may occur.
  7. Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue Rasuvo first and, if the lymphoma does not regress, appropriate treatment should be instituted.
  8. Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors.
  9. Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy.
  10. Potentially fatal opportunistic infections, especially Pneumocystis jiroveci pneumonia, may occur with methotrexate therapy.
  11. Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.


Rasuvo is contraindicated in the following:



Common adverse reactions are: nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leukopenia, pancytopenia, dizziness, photosensitivity, and “burning of skin lesions”. The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, and abdominal distress. Other frequently reported adverse reactions are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.




Rasuvo is for once weekly subcutaneous use only.

Administer Rasuvo in the abdomen or thigh.